GlassScriptPhysician profile
Viralkumar Amrutiya
NPI 1356832935
$1,553.01
in general payments reported to CMS, 2019-2025
15 companies · $992 in 2025
The $992 reported for 2025 was more than what 78% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $82.96 · 2023: $286 · 2024: $192 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,470.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $224.19 | 2023 | Benlysta |
| Novo Nordisk INC | $213.76 | 2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $186.19 | 2025 | Acthar |
| Vantive US Healthcare LLC | $152.47 | 2025 | Renal - Pd, Renal - Acute |
| Calliditas Therapeutics US INC. | $143.25 | 2025 | Tarpeyo |
| Nxstage Medical, INC. | $117.52 | 2025 | Pureflow Sl, Nxstage System One |
| Alexion Pharmaceuticals, INC. | $99.40 | 2022-2023 | Ultomiris |
| Akebia Therapeutics INC | $84.95 | 2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $74.36 | 2024 | |
| Novartis Pharmaceuticals Corporation | $73.08 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $71.31 | 2024-2025 | Jynarque |
| Veloxis Pharmaceuticals, INC. | $44.89 | 2023 | Envarsus |
| Fresenius USA Marketing, INC. | $23.75 | 2025 | Velphoro |
| Astrazeneca Pharmaceuticals LP | $23.75 | 2025 | Farxiga |
| Daiichi Sankyo INC. | $20.14 | 2024 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Viralkumar Amrutiya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.